Company Overview and News


Add NBRV
to your dashboard

Headline News

3 Biotechs For The January Effect

2018-01-03 seekingalpha
In my view, three biotech microcaps may yield among the best risk/reward scenarios for investors today. (182-3)

Achaogen: Rebound Likely In 2018

2017-12-24 seekingalpha
Continued weakness in the space highlighted by the bargain sale of The Medicines Company's antibiotic portfolio worked against the stock in 2017. (133-61)

Nabriva Set To Have A Breakthrough 2018

2017-12-18 seekingalpha
After completing a successful Phase 3 (LEAP 1) study for its novel semi-synthetic pleuromutilin antibiotic, Lefamulin, Nabriva (NASDAQ:NBRV) released top-line results in September showing it met both the FDA primary endpoint of non-inferiority to Moxifloxacin (NI, 12.5% margin) in the treatment of moderate to severe community-acquired bacterial pneumonia, "CABP," and the EMA co-primary endpoints of non-inferiority to Moxifloxacin (NI, 10. (12-1)

Stocks To Watch: Tax Reform Heads To The Finish Line

2017-12-16 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn on the e-mail alert on to receive this article in your inbox every Saturday morning. (880-7)

Your Daily Pharma Scoop: Teva Q3 Results, Boost For RedHill, Clovis Reports Rubraca Sales

2017-11-02 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (685-3)

Major Biotech, Pharma and FDA Catalysts Coming in October

2017-09-30 247wallst
Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount of risk involved, should a study come back negative or should a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be massive upside. (212-13)

ROTY Volume 1 Edition 33: New Leadership In The Model Account, Changes To Format And Trades

2017-09-28 seekingalpha
I've made the switch to utilizing Tipranks Smart Portfolio for the ROTY model account and FinViz for tracking Contenders. (144-4)

Nabriva Looks To Another Phase 3 To Seal The Deal

2017-09-21 seekingalpha
Another phase 3 catalyst is expected to be read out in Spring of 2018, testing oral lefamulin against oral Moxifloxacin. (47-3)

ROTY Volume 1 Edition 32: Learning From Mistakes And Additional Trades

2017-09-21 seekingalpha
One of the ROTY full positions received a key analyst upgrade and has data coming soon. (59-2)

Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook

2017-09-20 zacks
A key development this week was the FDA approval of the first cancer biosimilar - Amgen (AMGN - Free Report) and Allergan’s Mvasi, a biosimilar version of Roche’s blockbuster cancer drug, Avastin. Other updates include important data presentations from companies like Nabriva Therapeutics (NBRV - Free Report) and AbbVie (ABBV - Free Report) . Recap of the Week’s Most Important Stories First Cancer Biosimilar Gets FDA Nod: The FDA approved Amgen and Allergan’s Mvasi, a biosimilar version of Roche’s blockbuster cancer drug, Avastin (bevacizumab). (305-0)

Corporate News Blog - Nabriva Therapeutics Declares Positive Top-line Results from Phase-3 Clinical Trial Evaluating Lefamulin for the Treatment of CABP

2017-09-20 accesswire
LONDON, UK / ACCESSWIRE / September 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Nabriva Therapeutics PLC (NASDAQ: NBRV) ("Nabriva"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=NBRV. The Company announced on September 18, 2017, positive top-line results from the Lefamulin evaluation against pneumonia (LEAP-1) trial. (39-0)

Nabriva Therapeutics: Buy The Secondary Offering

2017-09-19 seekingalpha
Future catalysts include upcoming presentations at scientific meetings and data from the second pivotal trial in Spring of 2018. (12-1)

Nabriva's Lefamulin Positive in Pivotal Study, Stock Surges

2017-09-19 zacks
Nabriva Therapeutics plc (NBRV - Free Report) announced results from a phase III study where lefamulin demonstrated non-inferiority to Bayer AG’s (BAYRY - Free Report) Avelox in treating patients with community-acquired bacterial pneumonia (“CABP”). (62-3)

ROTY Volume 1 Edition 31: Swapping Out Holdings For Contenders

2017-09-19 seekingalpha
The Contenders List is growing with several new tickers added, some of which are more interesting to me than current ROTY holdings. (117-0)

IFR Americas ECM Pipeline

2017-09-18 reuters
Sept 18, 2017 - NEAR-TERM CALENDAR September 19: Best (IPO-BSTI.O) (Cayman Islands/China, logistics) – $931.5m IPO. 62.1m ADSs (86.3% prim, 13.7% sec) at $13-$15. CITI, CS, GS, JPM, DB. NYSE “BSTI”. September 19: Daseke (US, transport/logistics) – $52m FO. 4.4m shares (91% prim, 9% sec) versus $12.96 last sale. STFL, COWN. September 19: Despegar.com (Argentina, online travel services) – $332m IPO. 12. (14-0)

CUSIP: 62957M104